𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation

✍ Scribed by Neeraj Saraf; M. Isabel Fiel; Graciela DeBoccardo; Sukru Emre; Thomas D. Schiano


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
377 KB
Volume
13
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Early histological recurrence of hepatitis C after liver transplantation (LT) has a negative impact on patient and graft survival. We report a case of histological recurrence of HCV occurring in the second week after LT. A 75-year-old woman with chronic HCV and hepatocellular carcinoma underwent LT with an organ from a 75-year-old HCV-negative deceased donor. After an uneventful early postoperative period, an increase in the transaminases was observed, and on postoperative day 9 day, the alanine aminotransferase (ALT) was 673 IU/mL and aspartate aminotransferase (AST) 300 IU/mL, with normal alkaline phosphatase and bilirubin. Analysis of liver biopsy samples showed diffuse necroinflammatory changes with acidophilic bodies and concomitant mild acute cellular rejection. Subsequently there was a further increase in the transaminases, and on postoperative day 13, the AST rose to 445 IU/mL and ALT to 992 IU/mL. Repeat biopsy was performed, and analysis of the samples revealed lymphocytic portal inflammation with lymphoid aggregates and mild interface hepatitis, parenchymal necrosis, activation of sinusoidal lining cells, and mild steatosis. The biopsy sample was characteristic for HCV recurrence. The HCV RNA level was 84,000,000 copies/mL, and markers for other viral causes were not present. The patient became jaundiced and her course progressively worsened. She died on day 87 after transplantation. To our knowledge, this is the earliest reported case of histological recurrence of HCV after LT. It illustrates the importance of older donor and recipient age in the same patient as cofactors for early HCV recurrence and poor outcome.


πŸ“œ SIMILAR VOLUMES


Recurrent and new hepatitis C virus infe
✍ James E. Everhart; Yuling Wei; Heather Eng; Michael R. Charlton; David H. Persin πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 60

Recurrence of hepatitis C virus infectio
✍ Paul Martin; Santiago J. MuΓ±oz; Adrian M. Di Bisceglie; Raphael Rubin; Jeanne G. πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 375 KB πŸ‘ 2 views

## Identification of the hepatitis C virus-the main cause of posttransfusion and sporadic non -A, non-B hepatitisand the development of a diagnostic serological test have allowed us to study possible recurrence of this type of hepatitis after liver transplantation. Six of 34 consecutive transplant

Early recurrence of hepatitis C virus in
✍ Lydia M. Petrovic πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 255 KB πŸ‘ 2 views

1. Early recurrence of hepatitis C is universal. 2. Typical histopathologic features of hepatitis C virus (HCV) and acute allograft rejection (AAR) exist. 3. Early recurrent HCV may be differentiated from AAR. 4. Liver biopsy plays a role in diagnosing HCV and AAR. 5. Risk factors for recurrent HCV

Recurrent hepatitis C virus infection af
✍ Vargas, Victor ;Krawczynski, Krzysztof ;Castells, Lluis ;Martinez, Nuria ;Esteba πŸ“‚ Article πŸ“… 1998 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 137 KB

## Background: The value of immunohistochemical methods to identify hepatitis C virus antigen (HCVAg) in liver tissue has not been established. We have evaluated the significance of HCVAg expression in livers of patients with transplants and recurrent hepatitis C virus (HCV) infection. Methods: Fo

Hepatitis C virus infection and lymphopr
✍ Nizar N. Zein; Rogelio G. Perez; Russel H. Wiesner πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 34 KB πŸ‘ 2 views

with treatment failures moving on to combination therapy (IFN/CMB). The primary difference between the two best strategies (IFN/CBM vs. CMB-G) was that the CMB-G strategy was more successful with those with genotype 1. Thus, the genotyping strategy reached more people with less responsive disease th

Long-term outcome of hepatitis C virus i
✍ K. H. BΓΆker; G. Dalley; M. J. Bahr; H. Maschek; H. L. Tillmann; C. Trautwein; K. πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 2 views

Carrier states without significant laboratory abnormali-We analyzed the long-term clinical course of 71 paties are observed in approximately 16%, biochemical abtients with RNA-positive hepatitis C virus (HCV) infecnormalities without symptoms are seen in 60%, and tion after liver transplantation. Pa